Effect of lipid modification on progression of coronary calcification

Journal of the American Society of Nephrology

Volumn 16, Issue 11 SUPPL. 2, 2005, Pages

  McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALCIUM ACETATE; CALCIUM CARBONATE; CERIVASTATIN; COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SEVELAMER;

ARTERY CALCIFICATION; ATHEROMA; CALCIFICATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIALYSIS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOKING; BLOOD; CALCINOSIS; CHRONIC KIDNEY FAILURE; DISEASE COURSE; HYPERCHOLESTEROLEMIA;

CALCINOSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE, CHRONIC;

EID: 33644837473     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005060664     Document Type: Review

References (26)

1. Stary HC: The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 11[Suppl E]: 3-19, 1990
2. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91: 1800-1809, 1993
3. Tanimura A, McGregor DH, Anderson HC: Calcification in atherosclerosis, I: Human studies. J Exp Pathol 2: 261-273, 1986
4. Tanimura A, McGregor DH, Anderson HC: Calcification in atherosclerosis, II: Animal studies. J Exp Pathol 2: 275-297, 1986
5. Hirsch D, Azoury R, Sarig S, Kruth HS: Colocalization of cholesterol and hydroxyapatite in human atherosclerotic lesions. Calcif Tissue Int 52: 94-98, 1993
6. Simons DB, Schwartz RS, Edwards WD, Sheedy PF, Breen JF, Rumberger JA: Noninvasive definition of anatomic coronary artery disease by ultrafast computed tomographic scanning: A quantitative pathologic comparison study. J Am Coll Cardiol 20: 1118-1126, 1992
7. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K: Coronary artery calcification: Pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation 94: 1175-1192, 1996
8. O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL Jr, Forrester JS, Douglas PS, Faxon DP, Fisher JD, Gregoratos G, Hochman JS, Hutter AM Jr, Kaul S, Wolk MJ: American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102: 126-140, 2000
9. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC: Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291: 210-215, 2004;
10. erratum in JAMA 291: 563, 2004
11. Nallamothu BK, Saint S, Bielak LF, Sonnad SS, Peyser PA, Rubenfire M, Fendrick AM: Electron-beam computed tomography in the diagnosis of coronary artery disease: A meta-analysis. Arch Intern Med 161: 833-838, 2001
12. Allison MA, Wright M, Tiefenbrun J: The predictive power of low-density lipoprotein cholesterol for coronary calcification. Int J Cardiol 90: 281-289, 2003
13. Allison MA, Wright CM: A comparison of HDL and LDL cholesterol for prevalent coronary calcification. Int J Cardiol 95: 55-60, 2004
14. Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, Rewers M: Progression of coronary artery calcification in type 1 diabetes: The importance of glycemic control. Diabetes Care. 26: 2923-2928, 2003
15. McCullough PA, Soman S: Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor? Kidney Int Suppl 90: S18-S24, 2004
16. Achenbach S, Ropers D, Fohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG: Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation. Circulation 106: 1077-1082, 2002
17. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339: 1972-1978, 1998
18. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291: 1071-1080, 2004
19. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S: Risks associated with renal dysfunction in coronary care unit patients. J Am Coll Cardiol 36: 679-684, 2000
20. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 62: 997-1004, 2002
21. Schoenhagen P, Tuzcu EM: Coronary artery calcification and end-stage renal disease: Vascular biology and clinical implications. Cleve Clin J Med 69[Suppl 3]: S12-S20, 2002
22. Reslerova M, Moe SM: Vascular calcification in dialysis patients: Pathogenesis and consequences. Am J Kidney Dis 41: S96-S99, 2003
23. McCullough PA, Sandberg KR, Yanez J: Determinants of vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review [Abstract]. Am J Kidney Dis 42: 227A, 2003
24. Chertow GM, Burke SK, Raggi P; for the Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
25. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 142: 95-104, 2005
26. Taylor AJ; for the ARBITER-2 Investigators: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2): A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. AHA Scientific Sessions Late Breaking Clinical Trials IV; November 10, 2004; New Orleans, LA